ライフサイエンスコーパス: tamsulosin

1 approaches that mitigate the risks posed by tamsulosin.

2 aract surgery after the use of alfuzosin and tamsulosin.

3 plus tamsulosin, 0.4%; tolterodine ER, 0.5%; tamsulosin, 0%; and placebo, 0%).

4 ventions: Ciprofloxacin, 500 mg twice daily; tamsulosin, 0.4 mg once daily; a combination of the 2 dr

5 catheterization was low (tolterodine ER plus tamsulosin, 0.4%; tolterodine ER, 0.5%; tamsulosin, 0%;

6 Tamsulosin 400 mug and nifedipine 30 mg are not effectiv

7 assigned by a remote randomisation system to tamsulosin 400 mug, nifedipine 30 mg, or placebo taken d

8 herapy, including alpha-adrenergic blockers (tamsulosin), 5alpha-reductase inhibitors (finasteride),

9 edications including alpha-blockers (such as tamsulosin), 5alpha-reductase inhibitors (such as finast

10 nst prostate tumor epithelial cells, whereas tamsulosin, a sulfonamide-based alpha1-adrenoceptor anta

11 eptor antagonists, doxazosin, terazosin, and tamsulosin, against prostate cancer cell growth.

12 symptomatic LUTS/BPH: terazosin, doxazosin, tamsulosin, alfuzosin and silodosin.

13 Tamsulosin, alfuzosin slow release and silodosin do not

14 with urinary symptoms is alpha-blockers (eg, tamsulosin, alfuzosin; DeltaNIH-CPSI score difference vs

15 arkinson disease when compared with users of tamsulosin, an a1 adrenergic receptor antagonist of a di

16 ularly prevalent among patients treated with tamsulosin, an alpha-1A blocker prescribed for the treat

17 Although both tamsulosin and alfuzosin significantly increase the risk

18 We studied 15 and 25 patients administered tamsulosin and alfuzosin, respectively, as well as 25 co

19 ted the association between alpha1-ARAs like Tamsulosin and increased surgical risks for patients und

20 e treatment and placebo (p=0.78), or between tamsulosin and nifedipine (p=0.77).

21 cluded that the smooth muscle relaxant drugs tamsulosin and nifedipine assisted stone passage for peo

22 strong association exists between the use of tamsulosin and the occurance of intraoperative floppy ir

23 rease awareness of the risks associated with tamsulosin, and educational initiatives have fostered th

24 vir led to increased exposures of doxazosin, tamsulosin, and/or quetiapine, resulting in additional a

25 eriods before and after the first reports of tamsulosin-associated IFIS.

26 For example, alpha-blockade (eg, tamsulosin) combined with 5alpha-reductase inhibition (e

27 Patients receiving tolterodine ER plus tamsulosin compared with placebo experienced significant

28 Patients receiving tolterodine ER plus tamsulosin demonstrated significant improvements on the

29 Ciprofloxacin and tamsulosin did not substantially reduce symptoms in men

30 ract surgical adverse events over time among tamsulosin-exposed and non-tamsulosin-exposed patients a

31 f cataract surgical complications among both tamsulosin-exposed and non-tamsulosin-exposed patients d

32 s over time among tamsulosin-exposed and non-tamsulosin-exposed patients adjusting for patient-, surg

33 ations among both tamsulosin-exposed and non-tamsulosin-exposed patients declined between 2003 and 20

34 tments to decrease adverse event rates among tamsulosin-exposed patients.

35 evere IFIS was noted in 34.3% (24/70) of the tamsulosin eyes and in 16.3% (7/43) of the alfuzosin eye

36 gest that treatment with tolterodine ER plus tamsulosin for 12 weeks provides benefit for men with mo

37 weeks, compared with 307 (81%) of 378 in the tamsulosin group (adjusted risk difference 1.3% [95% CI

38 eters were reduced significantly only in the tamsulosin group (by 1.09+/-0.31 mm [P=.001] and by 0.89

39 y reduced by 0.70+/-0.20 m/s (P=.001) in the tamsulosin group and by 0.54+/-0.18 m/s (P=.004) in the

40 A total of 226 eyes (70 in the tamsulosin group, 43 in the alfuzosin group, and 113 in

41 er stimulation (5.23+/-2.42%, P=.035) in the tamsulosin group.

42 poptosis in a dose-dependent manner, whereas tamsulosin had no effect on prostate cell growth.

43 However, prior research on tamsulosin has suggested that it may in fact potentiate

44 Patients treated with tamsulosin have a higher risk of wound dehiscence after

45 ilar indications (minoxidil for alopecia and tamsulosin hydrochloride for BPH); comparing finasteride

46 tiomers 20, 23, and 24 were less potent than tamsulosin in inhibiting contractions of rat prostate ti

47 omatic benign prostatic hyperplasia, such as tamsulosin, increase the risk of surgical complications

48 s was reversed by the alpha(1)-AR antagonist tamsulosin, indicating its dependence on bladder neck SM

49 Tamsulosin is associated with intraoperative floppy iris

50 Tamsulosin is more potent than alfuzosin in inducing IFI

51 tdilation pupil dynamics, demonstrating that tamsulosin is more potent than alfuzosin in inducing int

52 but much more selective at alpha(1a)-AR than tamsulosin (K(i) = 0.13 nM, alpha(1b)/alpha(1a) = 14.8,

53 t against Parkinson disease, but rather that tamsulosin may in some way potentiate Parkinson disease

54 ein-coupled receptor (GPCR) modulation using tamsulosin, metoprolol, and bromocriptine coadministrati

55 4 mg of tolterodine ER (n = 217), 0.4 mg of tamsulosin (n = 215), or both tolterodine ER plus tamsul

56 losin (n = 215), or both tolterodine ER plus tamsulosin (n = 225) for 12 weeks.

57 nistering an alpha-1A-adrenergic antagonist, Tamsulosin, on urodynamics.

58 ofloxacin (P = 0.15) or tamsulosin versus no tamsulosin (P > 0.2).

59 eiving placebo (P<.001), 146 (71%) receiving tamsulosin (P=.06 vs placebo), or 135 (65%) receiving to

60 Tamsulosin remains an important risk factor for cataract

61 172 men (80%) receiving tolterodine ER plus tamsulosin reported treatment benefit by week 12 compare

62 % confidence interval [CI] = 157.53-402.02), tamsulosin (ROR = 171.44, 95% CI = 143.12-205.36), and c

63 oxazosin (DOX; 0.01-1.0 mg/kg b.wt./day), or tamsulosin (TAM; 0.05-0.25 mg/kg b.wt./day) were injecte

64 vere IFIS statistically was more likely with tamsulosin than with alfuzosin (P = 0.036).

65 Among patients not recently exposed to tamsulosin, the risk of surgical adverse events also dec

66 Among patients exposed to tamsulosin, the risk of surgical adverse events decrease

67 ability of doxazosin and terazosin (but not tamsulosin) to suppress prostate cancer cell growth in v

68 ns, and iris hook use was similar in the two tamsulosin treated group.

69 conventional repeated eyedrops regiment for tamsulosin treated patients.

70 ence interval: 1.24-11.67, P = .0194) in the tamsulosin-treated group.

71 se sponge on perioperative pupil diameter in tamsulosin-treated patients undergoing elective cataract

72 -dilation PD was significantly reduced after tamsulosin treatment (P < .001).

73 were performed twice firstly before starting tamsulosin treatment and secondly at the 3rd month of ta

74 Tamsulosin treatment does not change the iris SMR thickn

75 n treatment and secondly at the 3rd month of tamsulosin treatment.

76 (P = .001) were reduced significantly after tamsulosin treatment.

77 Patients treated with tamsulosin underwent subgroup analysis.

78 % CI, 1.06-3.05) and for patients with prior tamsulosin use (odds ratio, 2.00; 95% CI, 1.09-3.69).

79 Carefully taking a history of tamsulosin use before cataract surgery is advised so tha

80 omplex cataract surgery and those with prior tamsulosin use had significantly higher odds of unplanne

81 y combined with another intraocular surgery, tamsulosin use) and surgeon-related factors (low surgica

82 Patients were classified as tamsulosin users (n = 45,380), terazosin/alfuzosin/doxaz

83 80).RESULTSIncidence of Parkinson disease in tamsulosin users was 1.53%, which was significantly high

84 oxacin versus no ciprofloxacin (P = 0.15) or tamsulosin versus no tamsulosin (P > 0.2).

85 mia was also observed with desmopressin when tamsulosin was the comparator (HR 12.10; 95% CI 6.54, 22

86 OCT1 was less stereoselective, although (R)-tamsulosin was transported by OCT1 with higher apparent

87 As a sensitivity analysis, tamsulosin was used as the comparator rather than oxybut

88 Patients using tamsulosin were dilated either with mydriatic-cocktail s

89 ve agonist oxymetazoline, and the antagonist tamsulosin, with resolutions range from 2.9 angstrom to